Status: Recruiting
Phase I, Open-labeled, Dose-escalation, Dose-expansion Study Evaluating the Safety, Tolerance, Pharmacokinetics, and Activity of IUAb190708 in Patients With Advanced or Recurrent Solid Tumors
This study is to evaluate a novel cytotoxic anti-PD-L1, IUAb190708, for the treatment of tumor
Participants needed: 90
Trial details
Phase: Phase 1Age: 18-75Biological sex: AllType: InterventionalSponsor: Jun ZhouUpdated: May 13, 2026Locations: 6
Eligibility criteria
Male or female adult, age 18 - 75, understanding and voluntarily signing an info... [+8]
Serious/active infection or infection requiring intravenous antibiotic treatment... [+18]